Alung technologies, inc.Manufactures the hemolung ras and catheter.The incident occurred in boston, massachusetts.The event led to the patient being transitioned to comfort measures, and eventually patient death.During therapy, a clinical study patient experienced worsening mixed hypoxic and hypercarbic respiratory failure.Respiratory status continued to worsen after all therapeutic options had been exhausted.The family decided to transition the patient to comfort measures only.Alung was not initially made aware of the adverse event as it was originally reported as unrelated to use of the device and seriousness was not reported.Device causality was deemed unrelated to use of the device.The data log from therapy has been retrieved and reviewed by both clinical and software engineering staff.Consistent blood flows and co2 removal were observed throughout therapy.There were high blood flow alarms intermittently throughout therapy, but rpms were adjusted accordingly.There were no unexpected alarms or critical errors.Therapy was provided as intended.Following this adverse event, the patient was transitioned to comfort measures only and the patient subsequently expired.This event was unrelated to use of the device.Alung will continue to monitor any issues as they are reported.This mdr is being filed in response to a retrospective view of all alung complaints, which identified that the reporting decision for this complaint was not correct.This mdr is being filed retrospectively to correct the error in the reporting decision.
|
Alung technologies, inc.Received a report of a patient experiencing worsening hypoxic and hypercarbic states leading to respiratory failure during therapy involving a hemolung ras.The patient was transitioned to comfort measures, given morphine, and this eventually led to patient death.
|